Click to see our news releases about special projects and other announcements.Read More
Journalists: We are at your service. Please contact us with your request.Connect
By using single-cell analysis to measure metabolic activities in rare disseminated tumor cells taken from non-small cell lung cancer (NSCLC) patients, ISB researchers and their collaborators can accurately predict how patients will respond to various cancer therapies, and how treatments will impact a patient’s physiological performance and survival.
By Martin Shelton ISB Editorial Board Member With the exception of cancers of the skin, mouth, and blood, it is difficult to detect cancer by sight or with a routine health screen. The natural variety that exists at the cellular level — even within cells of the same type — challenges our ability to differentiate healthy tissue from diseased. This variety, what biologists call heterogeneity, means that equally healthy cells…